We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




An Electrochemical Bio-barcode Device for Home Disease Monitoring and Diagnosis

By LabMedica International staff writers
Posted on 28 Oct 2020
A point-of-care (POC) electrochemical bio‐barcode device and assay system have been developed to enable analysis of protein biomarkers in undiluted and unprocessed human plasma samples.

There is a need for biosensing systems that can be operated at the POC for disease screening and diagnostics and health monitoring. More...
In spite of this, simple to operate systems with the required analytical sensitivity and specificity for clinical samples remain a rarity.

To correct this situation investigators at McMaster University (Hamilton, Canada) and Brock University (St. Catharines, Canada) devised an electrochemical bio‐barcode assay (e‐biobarcode assay) that integrated biorecognition with signal transduction using molecular (DNA/protein) machines and signal readout using nanostructured electrodes.

The design of the e‐biobarcode assay eliminated multistep processing and used a single step for analysis following sample collection into the reagent tube. In use, a drop of blood is added to a vial of reactive solution, and a small amount of the mixture is placed onto a strip and inserted into a reader. In minutes, the device determines the concentration of an antigen.

In the current study, the investigators demonstrated the clinically relevant determination of prostate specific antigen (PSA) - the biomarker for prostate cancer - in undiluted and unprocessed human plasma.

"This is another step toward truly personalized medicine," said senior author Dr. Leyla Soleymani, associate professor of engineering physics at McMaster University. "We are getting away from centralized, lab-based equipment for this kind of testing. This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples."

"Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis," said contributing author Dr. Feng Li, associate professor of chemistry at Brock University. "Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives."

The e‐biobarcode assay was described in the October 7, 2020, online edition of the journal Angewandte Chemie.

Related Links:
McMaster University
Brock University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Using blood samples and physical measures from children as young as 8, investigators identified protein signatures that mirrored adult biomarkers linked to irreversible cardiovascular disease (Image Credit: Shutterstock)

Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks

Cardiovascular, kidney, and metabolic disorders often begin with subtle biological changes that are difficult to recognize in childhood. Identifying these changes early... Read more

Microbiology

view channel
Image: Graphical Abstract (Zeyang Shen et al., Shotgun Metagenomics Reveals Skin Microbiome Composition and Function in Infant Atopic Disease, Allergy, 2026. DOI: 10.1111/all.70449)

Infant Skin Microbiome Show Links to Later Eczema and Food Allergies

Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.